Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer.
Lymph node invasion
Pelvic lymph node dissection
Prostate cancer
Prostate specific antigen
Radical prostatectomy
Testosterone
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
07
06
2018
accepted:
13
07
2018
entrez:
12
10
2019
pubmed:
12
10
2019
medline:
12
10
2019
Statut:
ppublish
Résumé
Prostate cancer (PCa) patients who are classified into the intermediate risk category represent a heterogeneous population needing further preoperative risk assessment. To evaluate clinical total testosterone (TT) associations with lymph node invasion (LNI) in intermediate risk PCa. Between November 2014 and July 2016, intermediate risk PCa was assessed in 154 patients who underwent extended pelvic lymph node dissection if the risk of LNI was higher than 5%. Clinical factors associated with the risk LNI were investigated by the multinomial logistic regression model. The risk of LNI was assessed higher than 5% in 40.9% of cases of whom 15.5% had LNI. In the multivariate model, the risk of LNI was independently increased by prostate specific antigen (OR = 1.185; p = 0.021) and TT (OR = 1.004; p = 0.036). As a result, TT was an independent factor that associated with LNI because it increased the risk of LNI by 4% for each increment unit of TT. Preoperative TT independently increased the risk of LNI in the intermediate risk class of PCa patients elected to radical prostatectomy and extended pelvic lymph node dissection. TT might be a useful preoperative factor for stratifying intermediate risk patients because of the positive association of TT with high grade tumors.
Identifiants
pubmed: 31602188
doi: 10.1159/000499303
pii: cur-0012-0216
pmc: PMC6738153
doi:
Types de publication
Journal Article
Langues
eng
Pagination
216-222Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Références
Br J Urol. 1996 Aug;78(2):161-8
pubmed: 8813905
Urol Int. 2014;93(3):269-78
pubmed: 24334919
Front Surg. 2016 Dec 16;3:65
pubmed: 28018903
Prostate Cancer Prostatic Dis. 2008;11(4):320-4
pubmed: 18490935
Prostate. 2017 Feb;77(2):234-241
pubmed: 27775173
N Engl J Med. 1987 Oct 8;317(15):909-16
pubmed: 2442609
Eur Urol. 2007 Jul;52(1):29-37
pubmed: 17448592
Urol Int. 2016;97(1):32-41
pubmed: 26998904
J Urol. 2002 Apr;167(4):1681-6
pubmed: 11912387
J Urol. 1998 Aug;160(2):449-53
pubmed: 9679896
Br J Cancer. 2014 Jul 15;111(2):213-9
pubmed: 25003663
Eur Urol. 2014 Oct;66(4):635-43
pubmed: 24411992
Urol Int. 2017;99(2):207-214
pubmed: 28245480
J Urol. 2003 Jun;169(6):2289-92
pubmed: 12771773
J Urol. 2015 Feb;193(2):403-13
pubmed: 25260832
Eur Urol. 2009 Jun;55(6):1251-65
pubmed: 19297079
Arch Pathol Lab Med. 2009 Oct;133(10):1568-76
pubmed: 19792046
Tumori. 2017 May 12;103(3):299-306
pubmed: 27716882
CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
pubmed: 4625049
Urol Int. 2017;99(2):215-221
pubmed: 28245478
J Urol. 1996 Dec;156(6):1969-71
pubmed: 8911367
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Eur Urol. 2012 May;61(5):1004-10
pubmed: 22366188
Eur Urol. 2012 Mar;61(3):480-7
pubmed: 22078338
Eur Urol. 2014 May;65(5):918-27
pubmed: 23721959
Urol Oncol. 2016 Nov;34(11):482.e1-482.e4
pubmed: 27423822
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Eur Urol. 2014 Jan;65(1):7-16
pubmed: 23582879